Abstract: The present invention relates to the treatment of leaky gut. More particularly, the invention provides compounds, and compositions thereof, for use in methods for the treatment of leaky gut and in methods for the treatment of a subclinical increase in gut permeability. The invention further provides compounds, and compositions thereof, for use in methods for the treatment of leaky gut syndrome. The invention further provides compounds, and compositions thereof, for use in methods for the improvement of at least one symptom associated with leaky gut syndrome. The present invention also relates to a method for treatment of leaky gut, a method for treatment of leaky gut syndrome, and a method for improving at least one symptom associated with leaky gut syndrome.

Abstract: Provided herein are methods for treating certain inflammatory and/or respiratory conditions, disorders and diseases in humans using compositions comprising lipopeptides, including microcolins. The compositions are orally administered. The humans suitable for such treatments include those largely resistant to medical and surgical interventions, such as steroid treatments. The compositions described herein have also been found to reduce cosinophil effector function.

Abstract: This disclosure provides, among other things, rotomeric isomers of 4-alkyl-5-heteroaryl-3H-1,2-dithiole-3-thiones, complexes of such isomers in which an individual rotomeric form is obtained by stabilization, and compositions comprising an excess of an individual rotomer (a rotomeric excess) as a stabilized complex. The disclosure also relates to methods of making and using: such rotomers and complexes, including methods of treating a human or animal patient with such rotomers or complexes thereof, e.g., to prevent, treat or reduce the symptoms of various disorders such as mucositis, viral infection, stroke injury, ischemia/reperfusion injury, cardiac ischemia and/or provide protection against oxidative damage in various organs and tissues for a medical purpose.

Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions. Taste-modified compositions also are provided.

Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions.

Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions. Taste-modified compositions also are provided.

Abstract: This disclosure provides, among other things, formulated oltipraz compositions comprising stabilized oltipraz crystals, for use in treating a patient who has a viral infection or is at risk of incurring a viral infection. Such viral infections can include a viral infection caused by a coronavirus such as one associated with MERS or SARS, e.g., SARS-CoV-2.

Abstract: Provided herein are methods for treating certain inflammatory and/or respiratory conditions, disorders and diseases in humans using salmonid oil compositions. The salmonid oil compositions are orally administered, and may be obtained from mild enzymatic hydrolysis of off-cuts of salmonid fish. The humans suitable for such treatments include those largely resistant to medical and surgical interventions, such as steroid treatments. The salmonid oil compositions described herein have also been found to reduce eosinophil effector function.

Abstract: This disclosure provides, among other things, formulated oltipraz compositions comprising stabilized oltipraz crystals, for use in treating a patient who has a viral infection or is at risk of incurring a viral infection. Such viral infections can include a viral infection caused by a coronavirus such as one associated with MERS or SARS, e.g., SARS-CoV-2.

Abstract: This disclosure provides, among other things, rotomeric isomers of 4-alkyl-5-heteroaryl-3H-1,2-dithiole-3-thiones, complexes of such isomers in which an individual rotomeric form is obtained by stabilization, and compositions comprising an excess of an individual rotomer (a rotomeric excess) as a stabilized complex. The disclosure also relates to methods of making and using: such rotomers and complexes, including methods of treating a human or animal patient with such rotomers or complexes thereof, e.g., to prevent, treat or reduce the symptoms of various disorders such as mucositis, and/or provide protection against oxidative damage in various organs and tissues for a medical purpose.

Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz, either in recrystallized or formulated crystal form, and a composition that reduces the rate of cellular oxygen consumption such as atovaquone, as well as methods of making such compositions, and methods of treating patients using such compositions. This disclosure also provides, among other things, compositions comprising quantities of oltipraz, either in recrystallized or formulated crystal form, for use in treating patients who may experience ischemia and/or reperfusion injury.

Abstract: The present invention relates to the use of turbine mixing during enzymatic hydrolysis of aquatic protein from species such as fish, aquatic mammals, crustaceans and/or mollusks, to obtain high quality aquatic protein hydrolysates, having very low oxidation, improved organoleptic profile and improved biological activity of interest, for human consumption and cosmetics. The turbine mixing can inhibit oxidation during hydrolysis, contribute to an increase in the bio-activity and decrease the bitter taste of the final product. The process can vary in starting material, pre-treatment, type and amount of enzyme, hydrolysis conditions, time, degree of hydrolysis and post-treatment.

Abstract: The present invention relates to the use of turbine mixing during enzymatic hydrolysis of aquatic protein from species such as fish, aquatic mammals, crustaceans and/or mollusks, to obtain high quality aquatic protein hydrolysates, having very low oxidation, improved organoleptic profile and improved biological activity of interest, for human consumption and cosmetics. The turbine mixing can inhibit oxidation during hydrolysis, contribute to an increase in the bio-activity and decrease the bitter taste of the final product. The process can vary in starting material, pre-treatment, type and amount of enzyme, hydrolysis conditions, time, degree of hydrolysis and post-treatment.

Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions.

Abstract: This disclosure provides, among other things, compositions comprising quantities of oltipraz crystals, as well as method of making such compositions, and method of treating patients using such compositions. Taste-modified compositions also are provided.

Abstract: The present invention relates to the use of turbine mixing during enzymatic hydrolysis of aquatic protein from species such as fish, aquatic mammals, crustaceans and/or mollusks, to obtain high quality aquatic protein hydrolysates, having very low oxidation, improved organoleptic profile and improved biological activity of interest, for human consumption and cosmetics. The turbine mixing can inhibit oxidation during hydrolysis, contribute to an increase in the bio-activity and decrease the bitter taste of the final product. The process can vary in starting material, pre-treatment, type and amount of enzyme, hydrolysis conditions, time, degree of hydrolysis and post-treatment.

Abstract: An improved herbicidal suspension concentrate comprising at least one anilide herbicide compound as the active ingredient and containing at least one carbamate compound as a crystallization suppressant, the resulting formulation exhibiting improved caking, gelling and settling properties and resulting in a more even distribution of active ingredient.

Abstract: A process for the isolation of low-molecular weight aminoglycan compound of formula I made up of alternating glucuronic acid and N- acetyl glucosamine units; from a hitherto unexploited natural source of waste egg shells; which process comprises the steps of: wherein M may be at one or more instances Na, Ca, K, Mg: and n is an integer between 20 and 40: (a) pre-preparation of the waste egg-shells for extraction of the embryonic low molecular weight aminoglycan compound of formula I using a polar organic solvent in water; (b) extraction of the low molecular weight aminoglycan compound of formula I as its water soluble salt using an aqueous polar salt solution; (c) isolation of a purified low molecular weight aminoglycan compound of formula I by gel formation out of the aqueous salt mixture by using a polar organic solvent followed by filtration or centrifuging; (d) stabilization of the isolated aminoglycan extract by sequential introduction of organic oils into a semi-dried gel to form the aminoglycan comp

Abstract: Processes for the isolation of low-molecular weight aminoglycan compound of formula I from a hitherto unexploited natural source of waste egg shells which is made up of alternating glucuronic acid and N-acetyl glucosamine units comprising the steps of: (a) pre-preparation of the waste egg-shells for extraction of the embryonic low molecular weight aminoglycan compound of formula I using a polar organic solvent in water; (b) extraction of the low molecular weight aminoglycan compound of formula I as its soluble salt using an aqueous polar salt solution; (c) isolation of a purified low molecular weight aminoglycan compound of formula I by gel formation out of the aqueous salt mixture by using a polar organic solvent followed by filtration or centrifuging; (d) stabilization of the isolated aminoglycan extract by sequential introduction of organic oils into a semi-dried gel to form ordered sheets of aminoglycan compound of formula I with no visible cross-linking of the carbohydrate polymer.

Abstract: Processes for preparing compounds of formula I are disclosed comprising the steps of: (a) forming of chiral propionic acid ester compounds of formula V.